Global Blood Cell Separation Market – Rising incidence of cancer is encouraging further research in the field, Advances in computer techniques etc. driving market growth - by PMI
January 12, 2021 23:05 ET | Source: PMI PMI Pune, INDIA
Covina, CA, Jan. 12, 2021 (GLOBE NEWSWIRE) The market is driven by the increasing use of cell separation in cancer research. In addition, the rising focus on personalized medicine is anticipated to further boost the growth of the cell separation market. The increasing use of cell separation in cancer research will be one of the major drivers in the global market.
The global blood cell separation market is estimated to be US$ 28.4 billion by 2029 and is anticipated to register a CAGR of 17.2%.
Pvsripo is a novel immunotherapy that activates patients’ innate and adaptive immune system to enable anti-tumor response and establish immunologic memory to prevent the recurrence of cancer.<br />
07.01.2021 - Completes recruitment of patients with 2nd line head and neck squamous cell carcinoma (HNSCC)Recruitment of additional 1st line non small cell lung cancer (NSCLC) patients startedFurther interim data from TACTI-002 expected in H1 2021 Sydney, . Seite 1
Interim data
Immutep reported that interim data from the TACTI-002 study was encouraging. Subsequently, while at the Society for Immunotherapy of Cancer, the company mentioned the second line HNSCC patient data was very robust and formed a basis for additional clinical development.
Lastly, Immutep notified the market that the TACTI-002 trial involving patients with first-line non-small cell lung cancer (NSCLC) had commenced. An additional 4 new patients have also been recruited, on top of the already 74 patients that were previously announced on 19 November. 40 of the 110 patients with first-line NSCLC have now been recruited for Part A of the TACTI-002 study.
The company expects further interim data from the TACTI-002 study in the first half of 2021.
SITC Statement on SARS-CoV-2 Vaccination and Cancer Immunotherapy
Share Article
The Society for Immunotherapy of Cancer (SITC) commends the global biomedical community for coming together to develop and authorize safe and effective SARS-CoV-2 vaccines at unprecedented speeds. SITC stands with the world in hoping that rapid vaccine deployment will help to end the global pandemic. MILWAUKEE (PRWEB) December 23, 2020 The Society for Immunotherapy of Cancer (SITC) commends the global biomedical community for coming together to develop and authorize safe and effective SARS-CoV-2 vaccines at unprecedented speeds. SITC stands with the world in hoping that rapid vaccine deployment will help to end the global pandemic.